Obicetrapib Reduces Cholesterol and Heart Attack Risk in 12 Weeks
TL;DR Summary
A new pill called Obicetrapib significantly lowers 'bad' LDL cholesterol and lipoprotein(a) levels in just 12 weeks, offering a promising treatment for high-risk heart patients, with results showing over 30% reduction and good tolerability.
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
3 min
vs 3 min read
Condensed
94%
590 → 34 words
Want the full story? Read the original article
Read on SciTechDaily